Home » Newsletters » BioWorld Science

BioWorld Science

June 6, 1997

View Archived Issues

Milkhaus reports results of leukemia trial

ImClone reaches milestone in small cell lung cancer treatment collaboration

Multikine progresses in clinical trials

DynaGen licenses smoking cessation technology

Update on Immunomedics diagnostic imaging products

Immunex reports anticancer activity of Flt3 ligand

FDA approves generic version of Diamox

Schering-Plough Research Institute reveals structure of enzyme in HCV life cycle

Maxygen: new biotechnology company

Fujisawa discloses agents for bone metabolism disorders

Takeda describes GnRH antagonists

Fibrinogen antagonists from Merck & Co.

Preparation and use of 5alpha-reductase type 1 inhibitors described by Merck & Co.

Agents for HIV, tumors and autoimmune diseases from Boehringer Mannheim

New influenza vaccine prepared by Yissum

Anti-HIV vaccines reported by Duke University

Olanzapine superior to haloperidol against negative symptoms in schizophrenia

Body weight positively correlated with cognitive performance in AD

First approval for new MRI contrast agent from Nycomed

Promising animal data reported for Mitsui Toatsu cerebroprotectant

LXR refocuses Lexirin development

r-metHuSCF + filgrastrim for PBPC mobilization and transplantation: a phase I/II trial

Potent LT biosynthesis inhibitors described by Abbott

Clinical trials for Albuterol Spiros completed

Lilly describes potent new SERM

Alpha2-antagonist effective in patients with Parkinson's disease

COMT inhibitor increases response to L-DOPA in patients with PD

Target enrollment reached in phase III trial of Interferon's Alferon N Injection

Tolerance to benzodiazepine hypnotics overcome with melatonin

Selective tumor targeting reported for Bexxar

Phase III results with Lilly's raloxifene reported

Encouraging phase II data with Connetics' ConXn reported

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Cosmo data positive for first new hair-loss approach in decades
BioWorld
Shares of Cosmo Pharmaceuticals NV rose sharply on Dec. 3 following top-line pivotal phase III data showing a statistically significant and clinically meaningful...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...